Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase II Study of Sequencing Abiraterone Acetate and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

Next Previous
Trial Profile

A Randomized Phase II Study of Sequencing Abiraterone Acetate and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 13 Sep 2021 Results assessing the impact of treatment with abiraterone or enzalutamide as well as HSD3B1 gene mutation on steroid hormones, quantified by mass spectrometry (MS) in patients with CRPCpresented at the 116th Annual Meeting of the American Urological Association
  • 03 Jun 2021 Results assessing acquired genomic contributors to cross-resistance in metastatic castration-resistant prostate cancer, published in the Clinical Cancer Research.
  • 06 Aug 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top